|
|
|
市場調査レポート
ブランドと戦略：非インスリン糖尿病薬
Brands & Strategies: Non-Insulin Antidiabetics
|
Abstract
Introduction:
The type 2 diabetes branded drug market was worth $7.7 billion in 2007 and is
set to undergo robust annualized growth of 5.7% over 2007-2012, reaching sales
of $10.1 billion in 2012. Despite this growth, key changes in the structure of
the market will occur. Sales of the once-leading PPAR-gamma agonists, Takeda' s
Actos and GlaxoSmithKline' s Avandia, will decline sharply as the agents
experience generic erosion. However, uptake of the DPP-IV inhibitor, Merck' s
Januvia, and GLP-1 analogue, Amylin/Eli Lilly' s Byetta, will fuel the
continuing growth in the market.
In this report, we cover branded agents for type 2 diabetes and exclude
insulin therapy from our study.
Questions Answered in This Report:
- Despite its relatively recent launch in 2006, Januvia garnered impressive
sales of $550.6 million in the major markets under study in 2007 and is set to
reach blockbuster status over our forecast period. What strategies has Merck
employed that have been integral to Januvia' s impressive sales? What
perceptions do physicians and patients have about Merck?
- Takeda will lose its status as the leading company in the type 2 diabetes
branded market; the company generated sales of $3.7 billion in 2007 but will
fall to second place among branded type 2 diabetes companies in the markets
under study with sales of $2.7 billion in 2012. What strategies will Takeda
implement to mitigate the loss in sales following the genericization of Actos?
Which company will surpass Takeda as the leading company in the type 2
diabetes branded market?
- In 2008, Amylin/Eli Lilly' s Byetta has been plagued by safety concerns,
including cases of potentially fatal acute pancreatitis. How have the reports
of acute pancreatitis affected physician and patient perception of Byetta, and
how do physicians and patients perceive Amylin and Eli Lilly in the branded
type 2 diabetes market?
- Companies use a range of strategies to position their names and brands in
the type 2 diabetes market, including pharmaceutical representative detailing,
providing samples to physicians, patient support programs, conference
presentation of clinical trial data, and brand messaging. Which of these
strategies have the greatest impact on physician and patient perception? Which
companies are perceived most positively among physicians for each of these
strategies?
Scope:
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom,
and Japan.
Companies covered: Alkermes, Eli Lilly, AstraZeneca, Bayer, Bristol-Myers
Squibb, Boehringer Ingelheim, Daiichi Sankyo, Dr. Reddy' s Laboratories,
GlaxoSmithKline, Isis Pharmaceuticals, Merck, Novartis, Novo Nordisk,
Ortho-McNeil (Johnson & Johnson), Pfizer, Sanofi-Aventis, and Takeda.
Brands and emerging agents covered: Actoplus Met, Actos, Avandamet, Avandaryl,
Avandia, Byetta, Duetact, Galvus, Glyset, Janumet, Januvia, Prandin, Precose,
Starlix, Symlin, Byetta LAR, and Victoza.
The report features analysis of each company' s type 2 diabetes product
portfolio, strategic positioning, and development pipeline. The report also
provides in-depth discussion of leading brands, sales and market position,
pricing and reimbursement, strengths/weakness/opportunities/threats (SWOT)
analysis, ongoing postmarketing clinical trials, and strategic initiatives.
Physician perception of key brands: Analysis of physician perceptions of the
type 2 diabetes drug market based on a custom survey of 71 U.S.-based primary
care physicians (PCPs) and 31 U.S.-based endocrinologists. The survey is
brand-focused and examines physician perceptions of key competitors, brand
attributes and messaging, and unmet needs.
Patient perception of key brands: Analysis of patient perceptions of type 2
diabetes drug therapy based on a custom survey of 252 U.S.-based patients. The
survey examines patients' perceptions of brand attributes, messaging, and
unmet needs.
Epidemiology: Total prevalent and diagnosed cases for type 2 diabetes in each
of the major markets are presented for 2007 and 2012. Total drug-treated cases
for type 2 diabetes in each of the major markets are presented in an
annualized forecast from 2007 to 2012.
Market forecast: Annualized sales forecasts for branded agents, including the
uptake of new agents, presented by region, company, and brand from 2007 to
2012.
Table of Contents
Executive Summary
- 2007 - 2012 Market Dynamics
- Competitive Landscape
- Brand Overview
- Physician and Patient Perspectives: Findings of Our Primary Research
Chapter 1. Introduction
- Scope of the Report
- Survey Methodology
- Physician Demographics
- Patient Demographics
Chapter 2. Competitive Analysis
- Overview of Competitive Landscape
- Physician Perception of Key Competitors
- Physician Perception of Key Brands
- Comparative Labeling for Key Brands
- Comparative Pricing of Key Brands
- Reimbursement Issues
- Promotional Spending
- Company - Specific Trends
- Brand - Specific Trends
- Physician Perceptions of Type 2 Diabetes Brand Promotion
Chapter 3. Primary Research with Key Stakeholders
- Physicians
- Key Drivers of Prescriber Decisions
- Sources of Information
- Response to Messaging
- Perceptions of Competitors
- Perceptions of Brands
- Unmet Needs in Type 2 Diabetes
- Patients
- Key Drivers of Brand Use
- Response to Messaging
- Perceptions of Brands
- Unmet Needs in Type 2 Diabetes
- Influential Factors Driving Stakeholder Behavior
- Comparison of Brand Perception
Chapter 4. Established Competitors
- Takeda
- Strategic Overview
- Goals and Vision in Type 2 Diabetes
- Type 2 Diabetes Product Portfolio
- Current Positioning
- Market Strategy and Outlook
- Actos
- Actos Competitive Analysis
- Physicians Inform Our Analysis
- Key Brand Strategies
- Future Positioning and Outlook
- ActoPlus Met
- Commercial Overview
- Future Positioning
- Duetact
- Commercial Overview
- Future Positioning
- Alogliptin
- Development and Commercial Overview
- Competitive Analysis
- Future Positioning and Outlook
- GlaxoSmithKline
- Strategic Overview
- Goals and Vision in Type 2 Diabetes
- Type 2 Diabetes Product Portfolio
- Current Positioning
- Market Strategy and Outlook
- Avandia
- Avandia Competitive Analysis
- Physicians Inform Our Analysis
- Key Brand Strategies
- Future Positioning and Outlook
- Avandamet
- Commercial Overview
- Future Positioning
- Avaglim/Avandaryl
- Commercial Overview
- Future Positioning
- Merck
- Strategic Overview
- Goals and Vision in Type 2 Diabetes
- Type 2 Diabetes Product Portfolio
- Current Positioning
- Market Strategy and Outlook
- Januvia
- Januvia Competitive Analysis
- Physicians Inform Our Analysis
- Key Brand Strategies
- Future Positioning and Outlook
- Janumet
- Commercial Overview
- Future Positioning
- Eli Lilly
- Strategic Overview
- Goals and Vision in Metabolism
- Type 2 Diabetes Product Portfolio
- Current Positioning
- Market Strategy and Outlook
- Byetta
- Byetta Competitive Analysis
- Physicians Inform Our Analysis
- Key Brand Strategies
- Future Positioning and Outlook
- Byetta LAR
- Development and Commercial Overview
- Byetta LAR Competitive Analysis
- Future Positioning and Outlook
Chapter 5. Minor Competitors
- Novartis
- Strategic Overview
- Goals and Vision in Metabolism
- Type 2 Diabetes Product Portfolio
- Current Positioning
- Market Strategy and Outlook
- Starlix
- Commercial Overview
- Future Positioning
- Galvus
- Commercial Overview
- Future Positioning
- Sciele Pharma
- Strategic Overview
- Current Positioning and Future Outlook
- Prandin
- Commercial Overview
- Future Positioning
- Bayer
- Strategic Overview
- Goals and Vision in Metabolism
- Type 2 Diabetes Product Portfolio
- Precose
- Commercial Overview
- Future Positioning
- Pfizer
- Strategic Overview
- Goals and Vision in Type 2 Diabetes
- Type 2 Diabetes Product Portfolio
- Glyset
- Commercial Overview
- Future Positioning
- Amylin
- Strategic Overview
- Goals and Vision in Metabolism
- Type 2 Diabetes Product Portfolio
- Symlin
- Commercial Overview
- Future Positioning
- Novo Nordisk
- Strategic Overview
- Goals and Vision in Metabolism
- Type 2 Diabetes Product Portfolio
- Current Positioning
- Market Strategy and Outlook
- Victoza
- Development and Commercial Overview
- Competitive Analysis
- Future Positioning and Outlook
Chapter 6. Emerging Competitors
- AstraZeneca
- Strategic Overview
- Goals and Vision in Metabolism
- Type 2 Diabetes Product Portfolio
- Onglyza
- Development and Commercial Overview
- Competitive Analysis
- Future Positioning and Outlook
- Dapagliflozin
- Development and Commercial Overview
- Competitive Analysis
- Future Positioning and Outlook
- Dapagliflozin/Metformin
- Commercial Overview
- Future Positioning
- Bristol - Myers Squibb
- Strategic Overview
- Goals and Vision in Metabolism
- Type 2 Diabetes Product Portfolio
- Ortho - McNeil
- Strategic Overview
- Type 2 Diabetes Product Portfolio
- Current Positioning and Future Outlook
- Metaglidasen
- Commercial Overview
- Future Positioning
- Dr. Reddy' s Laboratories
- Strategic Overview
- Type 2 Diabetes Product Portfolio
- Current Positioning and Future Outlook
- Commercial Overview
- Future Positioning
- Daiichi Sankyo
- Strategic Overview
- Type 2 Diabetes Product Portfolio
- Current Positioning and Future Outlook
- Rivoglitazone
- Commercial Overview
- Future Positioning
- Sanofi- Aventis
- Strategic Overview
- Type 2 Diabetes Product Portfolio
- Current Positioning and Future Outlook
- Lixisenatide (AVE - 0010)
- Commercial Overview
- Future Positioning
- Boehringer Ingelheim
- Strategic Overview
- Type 2 Diabetes Product Portfolio
- Current Positioning and Future Outlook
- Commercial Overview
- Future Positioning
- Isis Pharmaceuticals
- Strategic Overview
- Type 2 Diabetes Product Portfolio
- Current Positioning and Future Outlook
- Commercial Overview
- Future Positioning
Chapter 7. Market Forecast
- Type 2 Diabetes Market Analysis
- Sales by Region
- United States
- Europe
- Japan
- Sales by Class
- Sales by Brand
- Sales by Company
Appendices
- Epidemiology
- Prevalence and Diagnosis
- Major Market Statistics and Key Findings
- Abbreviations Used in this Report
- Bibliography
- Methodology
- Epidemiology
- Market Forecast
- Emerging Therapy Prices
- Companies Included in Competitive Analysis
- Revenue Allocation
Table of Exhibits
- Executive Summary
- Exhibit 1: Key Parameters of the Type 2 Diabetes Market
- Exhibit 2: Type 2 Diabetes Branded Market, ($US), Major Markets, 2007 -
2012
- Exhibit 3: Type 2 Diabetes Market Competitive Position, 2007 and 2012
- Exhibit 4: Type 2 Diabetes Market, by Company, as a Percentage of Total,
2007 and 2012
- Exhibit 5: Type 2 Diabetes Brand Sales ($US), by Brand, as a Percentage of
Total Brand Market Sales, 2007 and 2012
- Exhibit 6: Physician Rankings of Companies in Type 2 Diabetes Treatment
- Exhibit 7: PCP and Endocrinologist Rankings of Competitors in the Branded
Type 2 Diabetes Drug Market, Based on Company Attributes
- Exhibit 8: Patients' Top - of - Mind Type 2 Diabetes Agents
- Exhibit 9: Surveyed Physicians' Years of Practice
- Exhibit 10: Surveyed Physicians' Type 2 Diabetes Patients Treated per Month
- Exhibit 11: Surveyed Physicians' Geographic Distribution
- Exhibit 12: Surveyed Patients' Age
- Exhibit 13: Surveyed Patients' Gender
- Exhibit 14: Surveyed Patients' Years Receiving Treatment for Type 2
Diabetes
- Exhibit 15: Surveyed Patients' Severity of Type 2 Diabetes
- Exhibit 16: Surveyed Patients' Healthcare Providers
- Exhibit 17: Branded Type 2 Diabetes Agents Available in 2008
- Exhibit 18: Type 2 Diabetes Sales ($MM), by Country, 2007
- Exhibit 19: Type 2 Diabetes Market Share, by Company, 2007 and 2012
- Exhibit 20: Type 2 Diabetes Major - Market Sales ($US), by Company and
Brand, 2007 - 2012
- Exhibit 21: Physicians' Top - of - Mind Companies in the Branded Type 2
Diabetes Drug Market
- Exhibit 22: Physician Rankings of the Reputation of Competitors in the
Branded Type 2 Diabetes Drug Market
- Exhibit 23: Relative Importance of Company Attributes to Physicians
- Exhibit 24. Physician Ranking of Factors that Are Most Influential in the
Decision to Use a Specific Drug
- Exhibit 25: Physicians Overall Ranking of Companies According to Specific
Attributes (Top Seven Ranked Companies)
- Exhibit 26: Physicians Overall Ranking of Companies According to Specific
Attributes (Bottom Seven Ranked Companies)
- Exhibit 27: Physicians' Overall Ranking of Companies According to Specific
Attributes (Top Seven Ranked Companies), by Physician Type
- Exhibit 28: Percentage of Surveyed Physicians Who Identify Type 2 Diabetes
Brands as Their Top - of - Mind Brand
- Exhibit 29: Physicians' Familiarity with Type 2 Diabetes Brands
- Exhibit 30: Percentage of Physicians Prescribing Type 2 Diabetes Brands in
Each Line of Therapy
- Exhibit 31: Physician Rating of Marketed Type 2 Diabetes Therapies on
Various Efficacy, Safety/Side - Effect, Convenience, and Cost End Points
- Exhibit 32. Physician Ranking of the Five Most Important Factors that
Influence the Decision to Use a PPAR - Gamma Agonist
- Exhibit 33. Physician Ranking of the Five Most Important Factors that
Influence the Choice to Use a DPP - IV Inhibitor Rather than a GLP - 1 Analogue
- Exhibit 34. Physician Rating of Marketed Type 2 Diabetes Therapies on
Efficacy, Safety, and Convenience Factors on a Scale of 1 - 10
- Exhibit 35. Physician Ranking of the Five Most Important Factors that
Influence the Choice to Use One Meglitinide Over Another
- Exhibit 36. Physician Ranking of the Five Most Important Factors that
Influence the Choice to Use One Alpha Glucosidase Inhibitor over Another
- Exhibit 37. Physician Rating of FDCs on Safety and Convenience Factors on
a Scale of 1 - 10
- Exhibit 38: Physician Ranking of the Five Most Important Factors That
Affect the Decision to Use one FDC over Another in Type 2 Diabetes
- Exhibit 39: Label Indications for Key Type 2 Diabetes Brands
- Exhibit 40: Label Comparison Among Key Brands
- Exhibit 41: Current Price per Day ($US), Key Brands, 2007
- Exhibit 42: U.S. Formulary Status of Leading Type 2 Diabetes Drugs
- Exhibit 43: Surveyed Patients' Primary Prescription Drug Coverage
- Exhibit 44: Surveyed Patients' Payment for One Month Supply
- Exhibit 45: Percentage of Total Promotional Spend for Type 2 Diabetes
Therapies, by Company, 2007
- Exhibit 46: Promotional Spend for Type 2 Diabetes Therapies, by Brand, 2007
- Exhibit 47: Promotional Spending, by Competitor, as a Percentage of Total
Spending for Agents in Type 2 Diabetes, 2005 - 2007
- Exhibit 48: Physician Perception of the Type 2 Diabetes Brand with the
Most Promotional Material
- Exhibit 49: Preferred Information Sources for Physicians Who Treat Type 2
Diabetes
- Exhibit 50: Physicians' Top Channels to Gain Information About Type 2
Diabetes
- Exhibit 51: Physician Response to Marketing Messages for a Hypothetical
Type 2 Diabetes Brand
- Exhibit 52: Physician Perception of Most Influential Branded - Drug
Messaging in the Type 2 Diabetes Market
- Exhibit 53: Physician Rankings of Type 2 Diabetes Competitors
- Exhibit 54: Physician Ranking of the Top Seven Companies According to
Specific Attributes
- Exhibit 55: Physician Ranking of the Bottom Six Companies According to
Specific Attributes
- Exhibit 56: PCP Rankings of Top Seven Companies
- Exhibit 57: Endocrinologists Ranking of Top Seven Companies
- Exhibit 58: Physician Ranking of Activities That Have the Greatest Impact
on Their Willingness to Prescribe a Brand Once the Brand Is Approved
- Exhibit 59: Number of Months After Launch Physicians Prescribe a New Agent
- Exhibit 60: Anticipated Change in the Use of Type 2 Diabetes Agents Over
the Coming Year
- Exhibit 61: Physicians' Perceptions of Future Events' Impact on the Type 2
Diabetes Market, 2009 - 2012
- Exhibit 62: Physician Awareness of Emerging Therapies
- Exhibit 63: Physician Perceptions of Unmet Needs in Type 2 Diabetes
- Exhibit 64: Patients' Most - Trusted Sources for Type 2 Diabetes Drug
Information
- Exhibit 65: Sources for Type 2 Diabetes Drug Information Used By Patients
in the Past Three Months
- Exhibit 66: Patients' Response to Marketing Messages for a Type 2 Diabetes
Drug, Using Hypothetical "Brand X"
- Exhibit 67: Patients' Perception of Influential Messaging of Type 2
Diabetes Brands
- Exhibit 68: Patients' Top - of - Mind Type 2 Diabetes Agents
- Exhibit 69: Type 2 Diabetes Agents Specifically Requested by Patients
- Exhibit 70: Current and Previous of Type 2 Diabetes Agents Taken by
Patients
- Exhibit 71: Treatment - Experienced Patients' Perceptions of the Efficacy
and Tolerability of Type 2 Diabetes Agents
- Exhibit 72: Decision to Stop Taking Type 2 Diabetes Agents
- Exhibit 73: Percentages of Patients Reporting on the Type of Support
Programs Offered
- Exhibit 74: Support Patients Would Like in the Future to Assist in the
Management of Type 2 Diabetes
- Exhibit 75: Patient Perceptions of Unmet Needs in Type 2 Diabetes
Management
- Exhibit 76: Summary of Takeda' s Type 2 Diabetes Product Portfolio
- Exhibit 77: Physician Perceptions of Takeda in Type 2 Diabetes
- Exhibit 78: Physician Perceptions of Actos
- Exhibit 79: Ongoing Clinical Trials for Actos
- Exhibit 80: Actos Revenue ($US), 2007 - 2012
- Exhibit 81: Actos Revenue ($US), by Country, 2007 - 2012
- Exhibit 82: Actoplus Met Revenue ($US), 2007 - 2012
- Exhibit 83: Actoplus Met Revenue ($US), by Country, 2007 - 2012
- Exhibit 84: Duetact Revenue ($US), 2007 - 2012
- Exhibit 85: Duetact Revenue ($US), by Country, 2007 - 2012
- Exhibit 86: Physician Perceptions of Alogliptin
- Exhibit 87: Alogliptin Revenue ($US), 2007 - 2012
- Exhibit 88: Expected Alogliptin Revenue ($US), by Country, 2007 - 2012
- Exhibit 89: Alogliptin, Expected Price per Day ($US), by Country
- Exhibit 90: Summary of GlaxoSmithKline' s Type 2 Diabetes Product Portfolio
- Exhibit 91: Physician Perceptions of GlaxoSmithKline in Type 2 Diabetes
- Exhibit 92: Physician Perceptions of Avandia
- Exhibit 93: Ongoing Clinical Trials for Avandia
- Exhibit 94: Avandia Revenue ($US), 2007 - 2012
- Exhibit 95: Avandia Revenue ($US), by Country, 2007 - 2012
- Exhibit 96: Avandamet Revenue ($US), 2007 - 2012
- Exhibit 97: Avandamet Revenue ($US), by Country, 2007 - 2012
- Exhibit 98: Avandaryl Revenue ($US), 2007 - 2012
- Exhibit 99: Avandaryl Revenue ($US), by Country, 2007 - 2012
- Exhibit 100: Summary of Merck' s Type 2 Diabetes Product Portfolio
- Exhibit 101: Physician Perceptions of Merck in Type 2 Diabetes
- Exhibit 102: Physician Perceptions of Januvia
- Exhibit 103: Ongoing Clinical Trials for Januvia
- Exhibit 104: Januvia Revenue ($US), 2007 - 2012
- Exhibit 105: Januvia Revenue ($US), by Country, 2007 - 2012
- Exhibit 106: Janumet Revenue ($US), 2007 - 2012
- Exhibit 107: Janumet Revenue ($US), by Country, 2007 - 2012
- Exhibit 108: Summary of Eli Lilly' s Type 2 Diabetes Product Portfolio
- Exhibit 109: Physician Perceptions of Eli Lilly in Type 2 Diabetes
- Exhibit 110: Physician Perceptions of Byetta
- Exhibit 111: Ongoing Clinical Trials for Byetta
- Exhibit 112: Byetta Revenue ($US), 2007 - 2012
- Exhibit 113: Byetta Revenue ($US), by Country, 2007 - 2012
- Exhibit 114: Physician Perceptions of Byetta LAR
- Exhibit 115: Byetta LAR Revenue ($US), 2007 - 2012
- Exhibit 116: Expected Byetta LAR Revenue ($US), by Country, 2007 - 2012
- Exhibit 117: Byetta LAR, Expected Price per Day ($US), by Country
- Exhibit 118: Summary of Novartis' s Type 2 Diabetes Product Portfolio
- Exhibit 119: Starlix Revenue ($US), 2007 - 2012
- Exhibit 120: Starlix Revenue ($US), by Country, 2007 - 2012
- Exhibit 121: Galvus Revenue ($US), 2007 - 2012
- Exhibit 122: Galvus Revenue ($US), by Country, 2007 - 2012
- Exhibit 123: Summary of Sciele Pharma' s Type 2 Diabetes Product Portfolio
- Exhibit 124: Prandin Revenue ($US), 2007 - 2012
- Exhibit 125: Prandin Revenue ($US), by Country, 2007 - 2012
- Exhibit 126: Summary of Bayer' s Type 2 Diabetes Product Portfolio
- Exhibit 127: Precose Revenue ($US), 2007 - 2012
- Exhibit 128: Precose Revenue ($US), by Country, 2007 - 2012
- Exhibit 129: Summary of Pfizer' s Type 2 Diabetes Product Portfolio
- Exhibit 130: Glyset Revenue ($US), 2007 - 2012
- Exhibit 131: Glyset Revenue ($US), by Country, 2007 - 2012
- Exhibit 132: Summary of Amylin' s Type 2 Diabetes Product Portfolio
- Exhibit 133: Symlin Revenue ($US), 2007 - 2012
- Exhibit 134: Symlin Revenue ($US), by Country, 2007 - 2012
- Exhibit 135: Summary of Novo Nordisk' s Type 2 Diabetes Product Portfolio
- Exhibit 136: Physician Perceptions of Novo Nordisk in Type 2 Diabetes
- Exhibit 137: Physician Perceptions of Victoza
- Exhibit 138: Victoza Revenue ($US), 2007 - 2012
- Exhibit 139: Expected Victoza Revenue ($US), by Country, 2007 - 2012
- Exhibit 140: Victoza, Expected Price per Day ($US), by Country
- Exhibit 141: Summary of AstraZeneca' s Type 2 Diabetes Product Portfolio
- Exhibit 142: Physician Perceptions of Onglyza
- Exhibit 143: Onglyza Revenue ($US), 2007 - 2012
- Exhibit 144: Expected Onglyza Revenue ($US), by Country, 2007 - 2012
- Exhibit 145: Onglyza, Expected Price per Day ($US), by Country
- Exhibit 146: Physician Perceptions of Dapagliflozin
- Exhibit 147: Dapagliflozin Revenue ($US), 2007 - 2012
- Exhibit 148: Expected Dapagliflozin Revenue ($US), by Country, 2007 - 2012
- Exhibit 149: Dapagliflozin, Expected Price per Day ($US), by Country
- Exhibit 150: Dapagliflozin/Metformin Revenue ($US), 2007 - 2012
- Exhibit 151: Dapagliflozin/Metformin Revenue ($US), by Country, 2007 - 2012
- Exhibit 152: Summary of Bristol - Myers Squibb' s Type 2 Diabetes Product
Portfolio
- Exhibit 153: Summary of Competitor' s Type 2 Diabetes Product Portfolio
- Exhibit 154: Metaglidasen Revenue ($US), 2007 - 2012
- Exhibit 155: Metaglidasen Revenue ($US), by Country, 2007 - 2012
- Exhibit 156: Summary of Dr. Reddy' s Laboratories' Type 2 Diabetes Product
Portfolio
- Exhibit 157: Balaglitazone Revenue ($US), 2007 - 2012
- Exhibit 158: Balaglitazone Revenue ($US), by Country, 2007 - 2012
- Exhibit 159: Summary of Daiichi Sankyo' s Type 2 Diabetes Product Portfolio
- Exhibit 160: Rivoglitazone Revenue ($US), 2007 - 2012
- Exhibit 161: Rivoglitazone Revenue ($US), by Country, 2007 - 2012
- Exhibit 162: Summary of Sanofi- Aventis' s Type 2 Diabetes Product
Portfolio
- Exhibit 163: Lixisenatide Revenue ($US), 2007 - 2012
- Exhibit 164: Lixisenatide Revenue ($US), by Country, 2007 - 2012
- Exhibit 165: Summary of Competitor' s Type 2 Diabetes Product Portfolio
- Exhibit 166: Ondero Revenue ($US), 2007 - 2012
- Exhibit 167: Ondero Revenue ($US), by Country, 2007 - 2012
- Exhibit 168: Summary of Isis Pharmaceuticals' Type 2 Diabetes Product
Portfolio
- Exhibit 169: ISIS - 113715 Revenue ($US), 2007 - 2012
- Exhibit 170: ISIS - 113715 Revenue ($US), by Country, 2007 - 2012
- Exhibit 171: Type 2 Diabetes Market ($US), Major Markets, 2007 - 2012
(Tabular Format)
- Exhibit 172: Type 2 Diabetes Market ($US), Major Markets, 2007 - 2012
(Graphical Format)
- Exhibit 173: Timeline of Key Events, Type 2 Diabetes Market, 2007 - 2012
- Exhibit 174: U.S. Market Dynamics for Branded Type 2 Diabetes Drugs, by
Drug Class, 2007 - 2012
- Exhibit 175: European Market Dynamics for Branded Type 2 Diabetes Drugs,
by Drug Class, 2007 - 2012
- Exhibit 176: Japanese Market Dynamics for Branded Type 2 Diabetes Drugs,
by Drug Class, 2007 - 2012
- Exhibit 177: Branded Type 2 Diabetes Market ($US), by Country, 2007 - 2012
- Exhibit 178: Type 2 Diabetes Market ($US), by Drug Class, 2007 - 2012
- Exhibit 179: Type 2 Diabetes Market, by Drug Class, as a Percentage of
Total, 2007 and 2012
- Exhibit 180: PPAR - Gamma Agonist Market ($US), by Country, 2007 - 2012
- Exhibit 181: DPP - IV Inhibitor Market ($US), by Country, 2007 - 2012
- Exhibit 182: Meglitinide Market ($US), by Country, 2007 - 2012
- Exhibit 183: Fixed - Dose Combination Market ($US), by Country, 2007 - 2012
- Exhibit 184: Amylin Market ($US), by Country, 2007 - 2012
- Exhibit 185: Alpha Glucosidase Inhibitors Market ($US), by Country, 2007 -
2012
- Exhibit 186: Insulin Sensitizers Market ($US), by Country, 2007 - 2012
- Exhibit 187: SGLT2 Inhibitors Market ($US), by Country, 2007 - 2012
- Exhibit 188: Type 2 Diabetes Market ($US), by Brand, 2007 - 2012
- Exhibit 189: Branded Type 2 Diabetes Market ($US), by Brand, 2007 - 2012
- Exhibit 190: Branded Type 2 Diabetes Market ($US), by Company, 2007 - 2012
- Exhibit 191: Prevalent and Diagnosed Type 2 Diabetes Cases, Major Markets,
2007 - 2012
- Exhibit 192: Diagnosed Type 2 Diabetes Cases, by Country, Major Markets,
2007 - 2012
- Exhibit 193: Prevalent and Diagnosed Type 2 Diabetes Cases, by Country,
Major Markets, 2007 - 2012
- Exhibit 194: Adjusted Price of Actos ($US), 2007 - 2012
- Exhibit 195: Adjusted Price of Avandia ($US), 2007 - 2012
- Exhibit 196: Adjusted Price of Prandin ($US), 2007 - 2012
- Exhibit 197: Adjusted Price of Starlix ($US), 2007 - 2012
- Exhibit 198: Adjusted Price of Actoplus Met ($US), 2007 - 2012
- Exhibit 199: Adjusted Price of Avandaryl ($US), 2007 - 2012
- Exhibit 200: Adjusted Price of Avandamet ($US), 2007 - 2012
- Exhibit 201: Adjusted Price of Precose ($US), 2007 - 2012
- Exhibit 202: Adjusted Price of Glyset ($US), 2007 - 2012
- Exhibit 203: Licensing Deals and Revenue Allocation
|
 |
